Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics

Definitions

• This invention relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
• NAFLD non-alcoholic fatty liver disease
• NASH non-alcoholic steatohepatitis
• Non-alcoholic fatty liver disease is a disorder affecting as many as 1 in 3 - 5 adults and 1 in 10 children in the United States, and refers to conditions where there is an accumulation of excess fat in the liver of people who drink little or no alcohol.
• the most common form of NAFLD is a non-serious condition called hepatic steatosis (fatty liver), in which fat accumulates in the liver cells: although this is not normal, by itself it probably does not damage the liver.
• NAFLD most often presents itself in individuals with a constellation of risk factors called the metabolic syndrome, which is characterized by elevated fasting plasma glucose (FPG) with or without intolerance to post-prandial glucose, being overweight or obese, high blood lipids such as cholesterol and triglycerides (TGs) and low high-density lipoprotein cholesterol (HDL-C) levels, and high blood pressure; but not all patients have all the manifestations of the metabolic syndrome.
• FPG fasting plasma glucose
• TGs cholesterol and triglycerides
• HDL-C low high-density lipoprotein cholesterol
• NAFLD Newcastle disease virus
• the diagnosis of NAFLD is usually first suspected in an overweight or obese person who is found to have mild elevations in their liver blood tests during routine testing, though NAFLD can be present with normal liver blood tests, or incidentally detected on imaging investigations such as abdominal ultrasound or CT scan. It is confirmed by imaging studies, most commonly a liver ultrasound or magnetic resonance imaging (MRI), and exclusion of other causes.
• MRI magnetic resonance imaging
• NASH non-alcoholic steatohepatitis
• NAFLD may be differentiated from NASH by the NAFLD Activity Score (NAS), the sum of the histopathology scores of a liver biopsy for steatosis (0 to 3), lobular inflammation (0 to 2), and hepatocellular ballooning (0 to 2).
• NAS NAFLD Activity Score
• a NAS of ⁇ 3 corresponds to NAFLD
• 3 - 4 corresponds to borderline NASH
• >5 corresponds to NASH.
• the biopsy is also scored for fibrosis (0 to 4).
• NASH is a leading cause of end-stage liver disease; while NAFLD, and to an even greater degree NASH, are intimately related to states of the metabolic syndrome, including insulin resistance (pre-diabetes) and type 2 diabetes mellitus (T2DM), and abdominal obesity.
• T2DM has been the most prominent predictor for a poor prognosis in NAFLD, whereas elevated liver enzymes are considered unreliable.
• NASH develops much more frequently in the presence of longstanding T2DM, and the majority of patients with cryptogenic cirrhosis are obese and/or diabetic. Studies have demonstrated that 60% of patients with T2DM and NAFLD had biopsy-proven NASH, and that advanced hepatic fibrosis was present in 75% of those with diabetes and hypertension compared to only 7% without either condition.
• Haukeland
• NASH is an overlooked complication of T2DM that is frequently associated with fibrosis and in approximately 10% of patients results in cirrhosis; while the risk of hepatocellular carcinoma is also increased in patients with T2DM and NASH.
• Patients with NAFLD and NASH usually demonstrate mixed dyslipidemia and the other metabolic derangements described above, including an atherogenic low-density lipoprotein (LDL) phenotype consisting of predominantly of small dense particles.
• LDL low-density lipoprotein
• Both metabolic syndrome and NAFLD/NASH are characterized by increased cardiovascular inflammation as measured by elevations in high sensitivity C-reactive protein (hsCRP) and other inflammatory cytokines.
• hsCRP high sensitivity C-reactive protein
• pioglitazone is also associated with a significantly increased risk of weight gain, edema, congestive heart failure, and osteoporotic fractures in both women and men.
• GW510516 a potent peroxisome proliferator- activated receptor- ⁇ (PPAR5) agonist, ameliorated diet-induced obesity and insulin resistance in normal mice, an effect accompanied by enhanced metabolic rate and fatty acid ⁇ -oxidation. It also markedly improved diabetes as evidenced by substantial reductions in both glucose and insulin levels in genetically obese ob/ob mice.
• PPAR5 peroxisome proliferator- activated receptor- ⁇
• GW510516 has been shown in two Phase 1 studies in healthy subjects to reduce TGs, low-density-lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and insulin levels, and improve HDL-C and insulin sensitivity, with one of the studies also showing a 20% reduction in hepatic fat; while a later study confirmed these effects in dyslipidemic subjects with abdominal obesity (reduction in hepatic fat by 20%, 30% decrease in fasting TGs, 26% reduction in apoB, 23% reduction in LDL-C, 40% reduction in fasting non-esterified fatty acids, and 11% decrease in fasting insulin).
• LDL-C low-density-lipoprotein cholesterol
• apoB apolipoprotein B
• insulin levels and improve HDL-C and insulin sensitivity
• the lipid-modifying efficacy of GFT505 has been confirmed in both healthy subjects, as well as in patients with T2DM, combined abdominal obesity and mixed dyslipidemia, combined abdominal obesity and pre-diabetes, atherogenic dyslipidemia, and insulin resistance. These effects include reduction in TGs, non-HDL-C, and total cholesterol, LDL-C, and apoB; and increases in HDL-C.
• GFT505 treatment decreased hepatic steatosis, inflammation, and fibrosis, and decreased liver dysfunction markers; while in clinical studies GFT505 has been reported to decrease a range of liver dysfunction markers including ALT, alkaline phosphatase (ALP), and ⁇ -glutamyl transferase (GGT).
• a 1-year liver biopsy-based Phase2b trial in NASH initially recruited patients for treatment with 80 mg/day of GFT505 or placebo, with an interim safety analysis at 6 months showing no safety issue that compromised the ongoing study; and a second recruitment phase has selected patients for treatment with 120 mg/day of GFT505 or placebo.
• Obeticholic acid 6 -ethylchenodeoxycholic acid
• OCA 6 -ethylchenodeoxycholic acid
• a semi- synthetic bile acid analog that is a highly potent farnesoid X receptor agonist
• MBX-8025 is the compound of the formula
• MBX-8025 has the chemical name (RJ-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)- thio)-2-methylphenoxy)acetic acid [IUPAC name as generated by CHEMDRAW ULTRA 12.0].
• MBX-8025 and its synthesis, formulation, and use is disclosed in, for example, US Patent No. 7301050 (compound 15 in Table 1, Example M, claim 49), US Patent No. 7635718 (compound 15 in Table 1, Example M), and US Patent No. 8106095 (compound 15 in Table 1, Example M, claim 14).
• Lysine (L-lysine) salts of MBX-8025 and related compounds are disclosed in US Patent No. 7709682 (MBX-8025 L-lysine salt throughout the Examples, crystalline forms claimed).
• MBX-8025 is an orally active, potent (2 nM) agonist of PPAR5, It is specific
• PPAR5 activation stimulates fatty acid oxidation and utilization, improves plasma lipid and lipoprotein metabolism, glucose utilization, and mitochondrial respiration, and preserves stem cell homeostasis.
• PPAR5 agonists such as MBX-8025, are suggested to treat PPAR5-mediated conditions, including "diabetes, cardiovascular diseases, Metabolic X syndrome, hypercholesterolemia, hypo-HDL-cholesterolemia, hyper-LDL- cholesterolemia, dyslipidemia, atherosclerosis, and obesity", with dyslipidemia said to include hypertriglyceridemia and mixed hyperlipidemia.
• MBX-8025 alone and in combination with atorvastatin significantly (P ⁇ 0.05) reduced apoB lOO by 20-38%, LDL by 18-43%, triglycerides by 26-30%, non-HDL-C by 18-41%, free fatty acids by 16-28%, and high-sensitivity C-reactive protein by 43-72%; it raised HDL-C by 1-12% and also reduced the number of patients with the metabolic syndrome and a preponderance of small LDL particles.
• MBX-8025 at 100 mg/day reduced LDL-C by 22% over the total population treated, the percentage reduction in LDL-C increased to 35% in the tertile with the highest starting LDL-C levels (187-205 mg/dL), and trend analysis on individual patient data confirmed a positive correlation between percentage reduction in LDL-C and starting LDL-C level.
• MBX-8025 reduced LDL-S/VS by 40-48% compared with a 25% decrease with atorvastatin; and MBX-8025 increased LDL-L by 34-44% compared with a 30% decrease with atorvastatin.
• MBX-8025 significantly reduced alkaline phosphatase by 32-43%, compared to reductions of only 4% in the control group and 6% in the ATV group; and significantly reduced ⁇ -glutamyl transpeptidase by 24-28%, compared to a reduction of only 3% in the control group and an increase of 2% in the ATV group.
• MBX-8025 corrects all three lipid abnormalities in mixed dyslipidemia: lowers TGs and LDL and raises HDL, selectively depletes small dense LDL particles (92%), reduces cardiovascular inflammation, and improves other metabolic parameters: increases insulin sensitivity (lowers HOMA-IR, fasting plasma glucose, and insulin), lowers ⁇ -glutamyl transpeptidase and alkaline phosphatase, significantly (>2-fold) reduces the percentage of subjects meeting the criteria for metabolic syndrome, and trends towards a decrease in waist circumference and increase in lean body mass, pattern I to pattern A; and from pattern B to pattern I or A, where LDL particle size pattern B is a predominant LDL particle size of less than 25.75 nm, pattern I is a predominant LDL particle size of from 25.75 nm to 26.34 nm, and pattern A is a predominant LDL particle size of greater than 26.34 nm, where the LDL particle size is measured by gradient-gel electrophoresis. Summary of the invention
• This invention is the treatment of NAFLD and NASH, comprising therapy with MBX-8025 or an MBX-8025 salt.
• MBX-8025 effectively enhances fatty acid ⁇ -oxidation and lowers serum apoB, LDL-C, TGs, non-esterified fatty acids, and hsCRP in clinical and in non-clinical studies, while raising HDL-C in humans, its use will be effective in the treatment of NAFLD and NASH.
• MBX-8025 will significantly decrease hepatic fat (assessed by MRI), reduce transaminases, multiple inflammatory cytokines, the hepatocellular apoptosis marker CK18, improve the LDL phenotype, and demonstrate improvement in multiple glycemic parameters including glycated hemoglobin (HbAlc), FPG, fasting insulin, and HOMA-IR. Because the presence of >6 hepatic fat content by MRI in obese subjects with insulin resistance is very predictive of both NAFLD and NASH, reduction of hepatic fat by treatment with MBX-8025 will be significant in the treatment of NAFLD and NASH.
• HbAlc glycated hemoglobin
• this invention is:
• a method of treating NAFLD or NASH by administering MBX-8025 or an MBX-8025 salt; MBX-8025 or an MBX-8025 salt for use in treating NAFLD or NASH;
• compositions for treating NAFLD or NASH comprising MBX-8025 or an MBX-8025 salt
• kits for treating NAFLD or NASH comprising compositions comprising MBX-8025 or an MBX-8025 salt.
• a "therapeutically effective amount" of MBX-8025 or an MBX-8025 salt means that amount which, when administered to a human for treating NAFLD or NASH, is sufficient to effect treatment for the NAFLD or NASH.
• Treating" or “treatment” of NAFLD or NASH in a human includes one or more of:
• the therapeutically effective amount for a particular subject varies depending upon the health and physical condition of the subject to be treated, the extent of the NAFLD or NASH, the assessment of the medical situation, and other relevant factors. It is expected that the therapeutically effective amount will fall in a relatively broad range that can be determined through routine trial. [0025] "MBX-8025" is described in paragraphs [0014] through [0017].
• Salts for example, pharmaceutically acceptable salts of MBX-8025 are included in this invention and are useful in the compositions, methods, and uses described in this application. These salts are preferably formed with pharmaceutically acceptable acids. See, for example, "Handbook of Pharmaceutically Acceptable Salts", Stahl and Wermuth, eds., Verlag Helvetica Chimica Acta, Ziirich, Switzerland, for an extensive discussion of pharmaceutical salts, their selection, preparation, and use. Unless the context requires otherwise, reference to MBX-8025 is a reference both to the compound and to its salts.
• MBX-8025 contains a carboxyl group, it may form salts when the acidic proton present reacts with inorganic or organic bases.
• the MBX-8025 is treated with an excess of an alkaline reagent, such as hydroxide, carbonate or alkoxide, containing an appropriate cation.
• Cations such as Na + , K + , Ca 2+ , Mg 2+ , and NH 4 + are examples of cations present in pharmaceutically acceptable salts.
• Suitable inorganic bases therefore, include calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
• Salts may also be prepared using organic bases, such as salts of primary, secondary and tertiary amines, substituted amines including naturally-occurring substituted amines, and cyclic amines including isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, and the like.
• organic bases such as salts of primary, secondary and tertiary amines, substituted amines including naturally-occurring substituted amines, and cyclic amines including isopropylamine, trimethylamine, diethylamine, triethy
• MBX-8025 has also been studied in clinical trials as its calcium salt.
• the MBX-8025 may be administered by any route suitable to the subject being treated and the nature of the subject's condition. Routes of administration include administration by injection, including intravenous, intraperitoneal, intramuscular, and subcutaneous injection, by transmucosal or transdermal delivery, through topical applications, nasal spray, suppository and the like or may be administered orally. Formulations may optionally be liposomal formulations, emulsions, formulations designed to administer the drug across mucosal membranes or transdermal formulations.
• Suitable formulations for each of these methods of administration may be found, for example, in "Remington: The Science and Practice of Pharmacy", 20th ed., Gennaro, ed., Lippincott Williams & Wilkins, Philadelphia, Pa., U.S.A. Because MBX-8025 is orally available, typical formulations will be oral, and typical dosage forms will be tablets or capsules for oral administration. As mentioned in paragraph [0017], MBX-8025 has been formulated in capsules for clinical trials.
• the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, preferably in unit dosage form suitable for single administration of a precise dosage.
• the compositions may contain suitable pharmaceutically-acceptable excipients, including adjuvants which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
• suitable pharmaceutically-acceptable excipients include adjuvants which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
• “Pharmaceutically acceptable excipient” refers to an excipient or mixture of excipients which does not interfere with the effectiveness of the biological activity of the active compound(s) and which is not toxic or otherwise undesirable to the subject to which it is administered.
• conventional excipients include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
• Liquid pharmacologically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in water or an aqueous excipient, such as, for example, water, saline, aqueous dextrose, and the like, to form a solution or suspension.
• the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary excipients such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate,
• the composition will generally take the form of a tablet or capsule, or it may be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used excipients such as lactose and corn starch.
• Lubricating agents such as magnesium stearate, are also typically added.
• the active agent may be combined with emulsifying and suspending excipients. If desired, flavoring, coloring and/or sweetening agents may be added as well.
• Other optional excipients for incorporation into an oral formulation include preservatives, suspending agents, thickening agents, and the like.
• a pharmaceutical composition of MBX-8025, or a kit comprising compositions of MBX-8025 is packaged in a container with a label, or instructions, or both, indicating use of the pharmaceutical composition or kit in the treatment of NAFLD and/or NASH.
• a suitable amount of MBX-8025 (calculated as the free acid) for oral dosing will be 20-200 mg/day, preferably 50-100 mg/day, for an adult subject with NAFLD or NASH. That is, a suitable amount of MBX-8025 for oral dosing will be similar to the amounts employed in clinical trials; though it is possible that the therapeutically effective amount may be higher in severe cases of NAFLD or NASH. Suitable reductions in dose toward the lower end of the outer range above will be made for subjects who are children, depending on such additional factors as age and body mass.
• Subjects with NAFLD or NASH are treated with doses of either 50 or 100 mg/day of MBX-8025 for 6 months.
• Subjects are permitted their usual other medications (e.g. antidiabetic medications such as metformin or sulfonamides) but not glitazones, PPAR agonists, OCA, or similar medications.
• the subjects are assessed before the study, and at intervals during the study, such as every 4 weeks during the study and 4 weeks after the last dose of the MBX-8025 therapy, for safety and pharmacodynamic evaluations.
• MRIs of the subjects' livers are taken every 4 weeks during the study and 4 weeks after completion of MBX-8025 dosing, to determine hepatic fat; and liver biopsies are taken before the study (to establish the diagnosis) and 4 weeks after completion of MBX-8025 dosing.
• blood is drawn and urine collected; and a standard metabolic panel, complete blood count, and standard urinalysis are performed. Blood is analyzed for total cholesterol, HDL-C, LDL-C, VLDL-C, TGs, apoB, and liver transaminases.
• the subjects also maintain health diaries, which are reviewed at each visit.
• the subjects show a dose-related improvement in their disease, as manifested by, for example, MRI and liver biopsy.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Hematology (AREA)
• Rheumatology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pain & Pain Management (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Separation Using Semi-Permeable Membranes (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Publications (1)

Family

ID=53373532

Family Applications (1)

Country Status (27)

Cited By (11)

Families Citing this family (54)

Citations (2)

Family Cites Families (18)

• 2015
  • 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
  • 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
  • 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
  • 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
  • 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
  • 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
  • 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
  • 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
  • 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en not_active Ceased
  • 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
  • 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
  • 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
  • 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
  • 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
  • 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
  • 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
  • 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
  • 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
  • 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
  • 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
  • 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
  • 2015-04-10 HR HRP20192299TT patent/HRP20192299T1/hr unknown
  • 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
  • 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
• 2016
  • 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
  • 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
  • 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
• 2017
  • 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
• 2018
  • 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
  • 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
• 2019
  • 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
  • 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
• 2020
  • 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active

Patent Citations (5)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events